<\/span><\/p>\n\n\n\n
Recently, Sanofi and TOHO PHARMACEUTICAL CO., LTD. (Headquarters: Tokyo; President and Representative Director: Akira Umada; hereinafter \u201cTOHO PHARMACEUTICAL\u201d), a pharmaceutical wholesaling subsidiary of TOHO HOLDINGS, conducted, with the cooperation of Central Japan Railway Company (JR Central) and West Japan Railway Company (JR West), a demonstration test of the emergency transportation of pharmaceuticals to disaster-affected areas using the Shinkansen on the assumption of road traffic restrictions and a shortage of truck drivers in the event of a disaster.<\/p>\n\n\n\n
\u30fbPurpose of the Demonstration Test
In the event of a large-scale disaster, road disruptions, traffic restrictions, and the breakdown of logistics networks pose significant challenges. However, the Shinkansen is an infrastructure system characterized by strong recovery capabilities and high punctuality. In this demonstration test, the effectiveness of a modal shift leveraging these characteristics of the Shinkansen was examined to assess the extent to which such a modal shift could contribute to the emergency transportation of life-related pharmaceuticals. On this occasion in particular, the test targeted Sanofi\u2019s insulin products, which require stringent temperature control. By using the temperature-controlled transport device SALM*2, developed by TOHO PHARMACEUTICAL, the demonstration was conducted on the assumption of a highly demanding transportation scenario requiring advanced quality control.<\/p>\n\n\n\n
\u30fbResults of the Demonstration Test
In this demonstration test, no operational delays or temperature deviations occurred throughout the entire process, including transportation by the Shinkansen from Tokyo Station to Hiroshima Station. In addition, temperature control within the SALM functioned properly, and no damage to product packaging or discrepancies in quantity were observed, resulting in the successful completion of smooth transportation. These results confirmed that a logistics operation combining the rapid delivery by and punctuality of the Shinkansen, which is characterized by strong recovery capabilities, with temperature-controlled transport technology can function effectively even in emergencies.
\nIn light of the positive results of this demonstration test, Sanofi and TOHO HOLDINGS will further deepen their partnership to realize a proactive BCP that ensures the uninterrupted supply of pharmaceuticals not only in normal times but also in emergencies. Through collaboration beyond industry boundaries, Sanofi and TOHO HOLDINGS will work together to build a more resilient and sustainable pharmaceutical supply system.
\u3010Overview of the Demonstration\u3011
Date Conducted: January 28, 2026\nCargo: Sanofi insulin products, namely Lantus\u00ae XR Injection SoloStar\u00ae and Lantus\u00ae Injection 100 Units\/mL\nEquipment Used: Temperature-controlled transport device SALM developed by TOHO PHARMACEUTICAL\nTransportation Route: From TOHO PHARMACEUTICAL Logistics Center, TBC DynaBASE (Tokyo) to TBC Hiroshima (Hiroshima Prefecture)\n*Shinkansen transportation between Tokyo Station and Hiroshima Station was conducted on the Nozomi service.\nRoles of Each Company: Sanofi provided the pharmaceuticals for transport.\nTOHO PHARMACEUTICAL conducted logistics operations at the departure and arrival sites.\nJR Central and JR West cooperated in transportation via the Shinkansen.\nItems Verified: (1) The feasibility of emergency transportation by the Shinkansen as an alternative means in the event of road network disruption during a disaster\n(2) Confirmation of the effectiveness of logistics operations using the Shinkansen to maintain a stable supply of pharmaceuticals<\/p>\n\n\n\n
*1 The Study Group for the Establishment of the BCP System: An organization comprising pharmaceutical wholesalers, pharmaceutical manufacturers, and logistics companies specializing in the distribution of prescription pharmaceuticals, whose members collaborate to build a resilient logistics network capable of ensuring uninterrupted supply even in emergencies.
*2 Temperature-controlled transport device SALM: A high-performance transport device that enables the stringent temperature control required in the transportation of pharmaceuticals without the use of an external power source.
\u3010About Sanofi\u3011
Sanofi is an R&D-driven, AI-enabled biopharmaceutical company committed to improving people\u2019s lives and delivering strong growth. Drawing on deep expertise in immunology, Sanofi provides medicines and vaccines that treat and prevent disease for hundreds of millions of people worldwide, while also focusing on building an innovative pipeline to enable further contributions. Guided by its mission, \u201cWe chase the miracles of science to improve people\u2019s lives,\u201d Sanofi addresses the challenges facing healthcare, the environment, and society, and strives to create positive change for its employees as well as for national and local communities.\nSanofi is listed on Euronext (EURONEXT: SAN) and the NASDAQ (NASDAQ: SNY).\nFor more information about Sanofi K.K., the Japanese affiliate of Sanofi, please visit https:\/\/www.sanofi.co.jp.<\/p>\n\n\n\n
\u3010About TOHO HOLDINGS\u3011
TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the Group slogan \u201cTotal Commitment to Good Health.\u201d TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.\n3\nThe Group has made it its social mission to ensure \u201csafe and secure distribution of pharmaceuticals,\u201d and is taking on the challenge of innovation in pharmaceutical distribution, including the active introduction of cutting-edge technology to its logistics centers and dramatic improvements in logistics efficiency through thorough automation.\nFor more information about TOHO HOLDINGS, please visit https:\/\/www.tohohd.co.jp\/en\/.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sanofi K.K. (Headquarters: Tokyo; President and Representative Director: Takahiko Iwaya; hereinafter \u201cSanofi\u201d) […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","vkexunit_cta_each_option":"","footnotes":""},"categories":[136],"tags":[],"class_list":["post-761","post","type-post","status-publish","format-standard","hentry","category-cate-others-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/posts\/761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/comments?post=761"}],"version-history":[{"count":9,"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/posts\/761\/revisions"}],"predecessor-version":[{"id":780,"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/posts\/761\/revisions\/780"}],"wp:attachment":[{"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/media?parent=761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/categories?post=761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tohoyk.co.jp\/en\/wp-json\/wp\/v2\/tags?post=761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}